Poly(ADP-ribose) in the skin and in melanomas.

Cutaneous melanoma (CM) and uveal melanoma (UM) represent the most aggressive pigment cell tumor types. Our investigation examined the signaling molecule poly(ADP-ribose) (PAR) in CM and UM. We have demonstrated PAR in keratinocytes, sebocytes, hair follicles, endothelial cells and in subcutaneous adipocytes in the normal skin indicating that PAR may regulate physiological functions in these cell types. Furthermore, CM cells were PAR positive and tumor invasion level/thickness of CM correlated with the PAR content of the cell nuclei, with higher Clark and Breslow indices and AJCC scores associating with higher PAR content. This correlation was especially marked in the samples of female patients. In UM tumors (n=12) a slight overall and strong perivascular PAR staining was observed with considerable individual variations. In view of recent successful clinical trials with PARP inhibitors as adjuvant chemotherapeutic agents, our results suggest that melanomas may display differential sensitivity towards this novel therapeutic modality which should be considered for the selection of patients.

[1]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[2]  É. Szabó,et al.  Dual role of poly(ADP‐ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  A. Harris,et al.  Phase I Study of the Poly(adp-ribose) Polymerase Inhibitor, Ag014699, in Combination Withtemozolomide in Patients with Advanced Solid Tumors Cancer Therapy: Clinical , 2022 .

[4]  A. Chalmers The potential role and application of PARP inhibitors in cancer treatment. , 2008, British medical bulletin.

[5]  Takami Sato,et al.  The biology and management of uveal melanoma , 2008, Current oncology reports.

[6]  A. Scriven,et al.  Sun safety: what are the health messages? , 2008, The journal of the Royal Society for the Promotion of Health.

[7]  H. Dao,et al.  Gender differences in skin: a review of the literature. , 2007, Gender medicine.

[8]  V. D’Hondt,et al.  Novel treatment strategies for malignant melanoma: a new beginning? , 2007, Critical reviews in oncology/hematology.

[9]  R. Swanson,et al.  Novel modulators of poly(ADP-ribose) polymerase. , 2006, Trends in pharmacological sciences.

[10]  Chin-Lin Hsu,et al.  Induction of cell apoptosis in 3T3-L1 pre-adipocytes by flavonoids is associated with their antioxidant activity. , 2006, Molecular nutrition & food research.

[11]  V. Schreiber,et al.  Poly(ADP-ribose): novel functions for an old molecule , 2006, Nature Reviews Molecular Cell Biology.

[12]  C. Glass,et al.  A Topoisomerase IIß-Mediated dsDNA Break Required for Regulated Transcription , 2006, Science.

[13]  M. Piris,et al.  Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. , 2006, Cancer research.

[14]  C. Leonetti,et al.  Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. , 2005, European journal of cancer.

[15]  K. Murthy,et al.  Gender Differences in the Endotoxin-Induced Inflammatory and Vascular Responses: Potential Role of Poly(ADP-ribose) Polymerase Activation , 2005, Journal of Pharmacology and Experimental Therapeutics.

[16]  G. Argenziano,et al.  Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. , 2005, Human pathology.

[17]  L. McCullough,et al.  Ischemic Nitric Oxide and Poly (ADP-Ribose) Polymerase-1 in Cerebral Ischemia: Male Toxicity, Female Protection , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  C. Szabó,et al.  Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation. , 2005, Cellular and molecular life sciences : CMLS.

[19]  G. Seigel,et al.  Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. , 2004, International journal of molecular medicine.

[20]  Changlian Zhu,et al.  PARP‐1 gene disruption in mice preferentially protects males from perinatal brain injury , 2004, Journal of neurochemistry.

[21]  G. de Murcia,et al.  The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[22]  Arun D. Singh,et al.  Sunlight exposure and pathogenesis of uveal melanoma. , 2004, Survey of ophthalmology.

[23]  A. Ormerod,et al.  Nitric oxide function in the skin. , 2004, Nitric oxide : biology and chemistry.

[24]  C. Szabó,et al.  Cytoprotective effect of gallotannin in oxidatively stressed HaCaT keratinocytes: the role of poly(ADP‐ribose) metabolism , 2004, Experimental dermatology.

[25]  C. Leonetti,et al.  Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  L. Csernoch,et al.  Role of intracellular calcium mobilization and cell-density-dependent signaling in oxidative-stress-induced cytotoxicity in HaCaT keratinocytes. , 2003, The Journal of investigative dermatology.

[27]  P. Elsner,et al.  Oxidative stress in malignant melanoma and non‐melanoma skin cancer , 2003, The British journal of dermatology.

[28]  R. Bakos,et al.  Sunburn, sunscreens, and phenotypes: some risk factors for cutaneous melanoma in southern Brazil , 2002, International journal of dermatology.

[29]  C. Szabó,et al.  The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors , 2002, Pharmacological Reviews.

[30]  B. Sümegi,et al.  Reduction of acute photodamage in skin by topical application of a novel PARP inhibitor. , 2002, Biochemical pharmacology.

[31]  D. Schadendorf Is There a Standard for the Palliative Treatment of Melanoma? , 2002, Oncology Research and Treatment.

[32]  A. Kozubík,et al.  Multiple biological effects of inhibitors of arachidonic acid metabolism on human keratinocytes , 2002, Archives of Dermatological Research.

[33]  É. Szabó,et al.  Detection of Poly(ADP-ribose) Polymerase Activation in Oxidatively Stressed Cells and Tissues Using Biotinylated NAD Substrate , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[34]  U. Reichert,et al.  Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development. , 2001, Molecular genetics and metabolism.

[35]  É. Szabó,et al.  Peroxynitrite production, DNA breakage, and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. , 2001, The Journal of investigative dermatology.

[36]  K. Hood,et al.  Does Experience Predict Knowledge and Behavior With Respect to Cutaneous Melanoma, Moles, and Sun Exposure? Possible Outcome Measures , 2000, Behavioral medicine.

[37]  M. Picardo,et al.  Antioxidant pattern in uveal melanocytes and melanoma cell cultures. , 1999, Investigative ophthalmology & visual science.

[38]  T. Kakizawa,et al.  Inhibition of Nuclear Receptor Signalling by Poly(ADP-Ribose) Polymerase , 1999, Molecular and Cellular Biology.

[39]  A. Kentsis,et al.  Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors. , 1999, The Journal of investigative dermatology.

[40]  I. Ahmed Malignant melanoma: prognostic indicators. , 1997, Mayo Clinic proceedings.

[41]  A. Kopf,et al.  Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical‐mole syndrome: a case‐control study , 1996, The British journal of dermatology.

[42]  Gernot Rassner,et al.  Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients , 1995, Cancer.

[43]  D. Moore,et al.  Nevus counting as a risk factor for melanoma: comparison of self-count with count by physician. , 1994, Journal of the American Academy of Dermatology.

[44]  M. Malanga,et al.  Poly(ADP-ribose) molecules formed during DNA repair in vivo. , 1994, The Journal of biological chemistry.

[45]  J. M. Murcia,et al.  Poly(ADP-ribose) polymerase: a molecular nick-sensor. , 1994, Trends in biochemical sciences.

[46]  D. Guerry,et al.  Disseminated melanoma--is there a new standard therapy? , 1992, The New England journal of medicine.

[47]  O. Janssen,et al.  Differentiation of 3T3-L1 pre-adipocytes induced by inhibitors of poly(ADP-ribose) polymerase and by related noninhibitory acids. , 1989, European journal of biochemistry.

[48]  É. Szabó,et al.  Poly(ADP-ribose) polymerase mediates inflammation in a mouse model of contact hypersensitivity. , 2009, The Journal of investigative dermatology.

[49]  M. Hottiger,et al.  The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. , 2008, Frontiers in bioscience : a journal and virtual library.

[50]  U. Förstermann,et al.  Involvement of NO in contact hypersensitivity. , 1998, International immunology.